Premium
Veterinary pharmacovigilance. Part 2. Veterinary pharmacovigilance in practice – the operation of a spontaneous reporting scheme in a European Union country – the UK, and schemes in other countries
Author(s) -
WOODWARD K. N.
Publication year - 2005
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.2005.00646.x
Subject(s) - pharmacovigilance , european union , adverse drug reaction , medicine , eu countries , member states , veterinary medicine , veterinary drug , business , accounting , pharmacology , adverse effect , drug , chemistry , international trade , chromatography
Veterinary pharmacovigilance, as it operates in the European Union (EU), covers a very broad remit, including adverse effects in treated animals, exposed humans and the environment, and in addition, it extends to cover the violation of maximum residue limits. The mainstay of veterinary pharmacovigilance is the spontaneous reporting scheme working along side other systems such as those reporting on residues surveillance. One of the most well established schemes in the EU is that operating in the UK and this paper examines the evolution of that scheme and some of its findings, data from other countries, and information available from the literature. It also tentatively examines the ways that pharmacovigilance can be used for regulatory purposes, and the contribution from pharmacoepidemiology.